GB2485862A - Preparation process of L-arginine-alpha-ketoglutarate by direct crystallisation from fermentation broth - Google Patents
Preparation process of L-arginine-alpha-ketoglutarate by direct crystallisation from fermentation broth Download PDFInfo
- Publication number
- GB2485862A GB2485862A GB1111221.6A GB201111221A GB2485862A GB 2485862 A GB2485862 A GB 2485862A GB 201111221 A GB201111221 A GB 201111221A GB 2485862 A GB2485862 A GB 2485862A
- Authority
- GB
- United Kingdom
- Prior art keywords
- ketoglutarate
- arginine
- solution
- fermentation
- aakg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 60
- 230000004151 fermentation Effects 0.000 title claims abstract description 60
- 238000002425 crystallisation Methods 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims description 27
- PGRNZHOQVAPMFX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N PGRNZHOQVAPMFX-WCCKRBBISA-N 0.000 title abstract description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 68
- 229930064664 L-arginine Natural products 0.000 claims abstract description 65
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 59
- 102100024626 5'-AMP-activated protein kinase subunit gamma-2 Human genes 0.000 claims abstract description 51
- 101000760987 Homo sapiens 5'-AMP-activated protein kinase subunit gamma-2 Proteins 0.000 claims abstract description 51
- 239000013078 crystal Substances 0.000 claims abstract description 50
- 238000001953 recrystallisation Methods 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000004090 dissolution Methods 0.000 claims abstract description 6
- 230000008025 crystallization Effects 0.000 claims description 37
- 239000000047 product Substances 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 30
- 238000001914 filtration Methods 0.000 claims description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000012043 crude product Substances 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 230000009920 chelation Effects 0.000 claims description 11
- 238000005516 engineering process Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 238000002845 discoloration Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000004042 decolorization Methods 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000005189 flocculation Methods 0.000 claims description 5
- 230000016615 flocculation Effects 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000002826 coolant Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 159000000013 aluminium salts Chemical class 0.000 claims description 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000008394 flocculating agent Substances 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 description 46
- 239000004475 Arginine Substances 0.000 description 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 17
- 235000009697 arginine Nutrition 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000003828 vacuum filtration Methods 0.000 description 9
- 238000011084 recovery Methods 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- -1 amino acid salt Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 230000037257 muscle growth Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NCRWNFFIHNRODM-SCGRZTRASA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N NCRWNFFIHNRODM-SCGRZTRASA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241001255907 Tonica Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000010129 solution processing Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/50—Polycarboxylic acids having keto groups, e.g. 2-ketoglutaric acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/10—Citrulline; Arginine; Ornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/14—Glutamic acid; Glutamine
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A method of preparing L-arginine-alpha-ketoglutarate (AAKG) is disclosed comprising adding L-arginine and α-ketoglutarate which are obtained as fermentation products from microbes, the method further comprising concentration in a vacuum, crystallisation, dissolution discolouration, re-crystallisation and crystal drying.
Description
PREPARATION PROCESS OF L-ARGININE-a-KETOGLUTARATE BY
DIRECT CRYSTALLIZATION FROM FERMENTATION BROTH
Field of the Invention
The present invention belongs to biotechnology field and involves a preparation technology of Arginine-Alpha-ketoglutarate.
Background of the Invention
L-arginine-alpha-ketoglutarate, Called AAKG, is white or yellow crystal, soluble in water, HC1 and NaOH solution, slightly soluble in ethanol and insoluble in acetone and ether, etc. L-arginine-ct-ketoglutarate is an amino acid salt health product with increasing sales in the international market. As the functional nutrition intensifying agent and hepatinica, it is mainly used as the tonica to improve physique, accelerate and resume rapid muscle growth, promoting the nutrition and energy absorption of hepatic cells, and maintaining normal liver function and etc. The main physiological mechanism is that AAKG can promote nitrogen monoxide level and muscular movement, and further accelerate rapid growth and rejuvenation of muscle, enhancing strength and energy.
There are two AAKG salts: I:1 and 2:1 mixture ratio (L-arginine: a-ketoglutarate), namely Mono arginine ketoglutarate (MAAKG) and Di-arginine ketoglutarate (DAAKG). Two AAKG salts have similar physicochemical property, but are different in function and application fields. The primary function of MAAKG is to increase the nitric oxide level in blood, stimulating vasorelaxation, and accelerating the muscle growth after exercise. As the exercise invigorator
I
health product, it is very popular in American market (http://www.rnirns.com/) DAAKG is a organic acid salt with multiple physiological functions. Applying high doses of DAAKG to hepatoeirrhosis patients can enhance detoxication function of liver, which can significantly reduce pEasma ammonia and phenol. The function is also confirmed in the treatment of ammonia poisoning or intensification liver detoxification in animal experiments. Comparing with the control group, the treatment group has higher survival rate and less coma symptom. Based on pharmacological analysis, toxicological evaluation, regeneration of animal hepatic tissue, in vivo detoxification and other animal experiments, a series of clinical studies on DAAKG hepatinica Euligen was performed by France Refarland Pharmaceutical Factory, in which significant curative effect on liver disease, alcoholism and their complications was observed.
As early as 1977, it was reported that liver detoxification of hepatocirrhosis patients could be improved when high dose arginine-LI -ketoglutarate was applied (Muting et al. Munch Mcd Wochensehr, 1977). In recent years, there has been increasing studies on the AAKG clinical application and metabolic mechanism. It is described in United States Patent USP 2005/0085498 Al that in animal experiment, arginine and glutamine level in skeletal muscles can be improved and immune system can be stimulated by supplementing AAKG. It is also shown in a research aiming at supplement of AAKG (15 g/d) to children that AAKG can improve growth hormone level, promote metabolism of insulin-like growth factor (IGF1), glutamine, glutamate and other aminoacid. The growth rate is significantly increased after 5-month supplement. Similarly, AAKG can promote growth hormone and insulin secretion of patients after surgery, the intermediary metabolism substance glutamine and proline can also promote wound recovery. In a research on the anti-catabolism ftinction of AAKG, 14 multiple-traumatism patients with high catabolic and enhanced metabolism participated in the experiment. 20g AAKG is supplied to patients in the test group. It is shown that protein transformation and blood level of insulin, growth substance, glutamine, praline, arginine and other free amino acids were also significantly improved. In addition, study on healthy male with a daily supplement of lOg AAKG, the insulin level was enhanced by 2030%. However, no improvement is observed in group with separated arginine or a-ketoglutarate supplement. It is indicated from in vitro cell culture that AAKG can significantly induce the growth of human fibroblasts, a cell similar to muscle fiber cell. There is a remarkable dose-effect, whereas arginine or a-ketoglutarate has no such characteristic (USP 2005/008 5498 Al).
Furthermore, in water solution, AAKG can be dissociated to form arginine and ct-ketoglutarate. Therefore, it can be utilized as donor for ct-ketoglutarate or arginine. Under certain condition, it can be applied as substitute of arginine or a-ketoglutarate. Arginine is an essential amino acid as well as material for the synthesis of protein and creatine in vivo, it is also an important metabolic intermidiate for urea cycle and a precursor of nitrogen monoxide, whereas ct-kctoglutarate has strong regulation effect on protein metabolism, also an important substance to promote tricarboxylic acid cycle. (United States Patent USP 7645742; USP 6905707; USP 7,645,742) There are three methods for the production of AAKG. The first method is direct mixing process, in which L-arginine and a-ketoglutarate are mixed according to molar ratio of 1:1 and 2:1. The product is simple mixture of arginine and ketoglutarate, in which no salt bond exists, and the product quality is greatly affected by raw material quality and mixture homogeneity. Therefore, this method is not used in medicine or food production. The second method is dissolution-lyophilization. L-arginine and a-ketoglutarate solution in certain concentration are mixed in certain molar ratio, and the solution is lyophilized into AAKG, in which two substances can form stable organic acid salt. However, due to its high energy eomsumption during the lyophilization process, this method is only applicable in the production of AAKG injection. Above two methods are described in Chinese patent 200710063477.4, 200710063478.9 and 200710063479.3. The third method is crystallization process. After the solution is mixed, the solution is concentrated or treated with organic solvent to reduce solubility of AAKG and obtain AAKG crystals, which shall be washed and dried to obtain AAKG product.
Product prepared by this method has high purity, and the product quality can be guaranteed. However, the process is complicated arid the cost is high (CN 101591271 A).
L-arginine and a-ketoglutarate required in preparation of AAKG in above three methods must meet the requirement of raw pharmaceutical material. Especially in previous two methods, the impurity can not be eliminated during preparation process, and, higher requirement on product quality control is therefore required.
The crystallization method becomes optimization method in preparation of AAKG.
Preparation method of L-arginine-ct-ketoglutarate crystallization is described in CN1O1591271A. L-arginine and a-ketoglutarate raw material purchased from the market were used to prepare solution mixture crystallization preparation. It is well known that present L-arginine on the market is extracted from hair (usually pig or human hair) acid hydrolysis. a-ketoglutarate is chemically synthesized from petroleum material. There are biosafety concerns in source of these two raw materials. Just as described in CNlOlOll372A, ct-ketoglutarate-arginine salt prepared from chemosynthcsis products and hair extracts raw material might not be suitable for health food.
SUMMARY OF THE INVENTION
The present invention is to overcome above problems in AAKG product and its preparation technology, provide a method to prepare AAKG from ferrnentative L-arginine, a-ketoglutarate raw material. L-arginine and ct-ketoglutarate in the fermentation broth are directly used as AAKG preparation raw material, instead of refined crystallization products.
In present invention, raw material L-arginine and a-ketoglutarate were fermentation products obtained from non-transgenic wild-type microbe metabolism and fermentation using starch glucose from plant as the carbon source, which is called fermentation broth. a-ketoglutarate and L-arginine in fermentation broth are mixed and chelated to form salt, then L-arginine-cz-ketoglutarate salt is prepared using general chemical isolation technique and equipment for direct crystallization.
The preparation processes comprise fermentation broth pretreatment, chelation, concentration, crystallization, dissolution discoloration, recrystallization, crystal dryness and other technical units. In pretreatment process of L-arginine fermentation liquid, microbial cells and macromolecule impurities arc eliminated.
Certain amount of same purified a -ketoglutarate ferment broth is added and mixed, which is called chelation. Evaporate and concentrate the mixture in vacuum, L-argininecz-ketoglutarate crude product could be obtained under cooling and crystallization condition. The crude products is dissolved and decolorized, and then recrystallized in organic solvent. Finally, L-arginine a-ketoglutarate in high purity can be obtained after drying process.
In the present invention, the mentioned fermentation liquid pretreatment technique unit is a process to respectively flocculate, filtrate or centrifuge L-arginine fermentation broth or a-ketoglutarate fermentation broth in accordance with common methods to remove cells and large solid particles and obtain clarified filter liquor. In flocculation operation, aluminum sulfate, CaC12, polyaerylamide, chitosan and other flocculants or other inorganic aluminium salt, molysitc, calcium salt and polymeric flocculant are adopt. In the mentioned filter operation, plate-and-frame filtering, vacuum filtering or band type filter devices, etc. are especially suitable for large scale preparation process. In the mentioned centrifugation operation, a centriftigation device for solid-liquid separation is especially suitable for small sample preparation process.
In the present invention, the mentioned chelation technology unit is the process to add certain ct-Icetoglutarate fermentation liquid or ct-ketoglutarate solution based on the L-argininc content in filter liquor. The molar content of ct-ketoglutarate is 0.3-A.5 times of L-arginine in the system.
In the present invention, the mentioned concentration technique unit is a process to concentrate solution with L-arginine and a-kctoglutarate so that AAKG can reach to a hyper-saturated state. The preferred concentration device is vacuum concentration, double-effect concentration or multiple-effect concentration equipment. The solution is concentrated to I 5%-'50% of original L-arginine solution volume.
In the present invention, the mentioned crystallization technology unit is to incubate the concentrated solution under S DC -15 DC for crystallization or use a crystallizer tank to cool solution with coolant. The crystallization process is controlled within 4-50 hours. In the end, adopt filtration or centrifugation to collect crystals.
In the present invention, the mentioned dissolution decolorization technology unit is to dissolve above crystals again in 2-5 times (by weight) de-ionized water, stir the mixture so that it can be dissolved completely. Add particle activated carbon into the mixture for discoloration. The amount of activated carbon amount added is equivalent to 0.5%3.0% of AAKG crystal quality. Stir and then heat the solution to 4O-90 ° for 20--'60 minutes. In the end, collect AAKG filter liquor through plate-and-frame filtering.
In the present invention, the mentioned recrystallization technology unit is to slowly add hydrophilicity organic solvent with l4 times of solution volume into above AAKG filter liquor. Perform recrystallization after incubation under room temperature or in refrigerator statically for 850h. Collect crystals through filtration and which the crystal for 23 times with small amount of cold and fresh solvent, The mentioned hydrophilicity organic solvents include ethanol, methanol, acetone, isopropanol, glycerol, acetonitrile etc, where the preferred solvent is ethanol or acetone.
In the present invention, the mentioned crystal dryness technology unit adopts vacuum drying, heated air circulation oven, flash drying or other devices for crystal dryness. The drying temperature is 50 °C 150 °C.
In the present invention, the mentioned fermentation liquid pretreatment, 1 5 chelation, concentration, crystallization, dissolution discoloration, recrystallization, crystal dryness and other technical units can be added eliminated, adjusted or combined properly.
In the present invention, raw materials L-arginine and a-ketoglutarate for preparing AAKG are fermentation products using starch glucose with plant origin as the carbon source and non-transgenie microbe (independently isolated wild-type microorganism, CN 03112896.3; CN 200310106298.6). The obtained fermented product L-arginine or ct-ketoglutarate are in high in purity and stable in quality.
Importantly, AAKG is prepared from non-hair source arginine and non-petroleum based a-ketoglutarate raw material. It can be applied in health food without biosafety and food safety issues.
In the present invention, L-arginine in fermentation liquid and a-ketoglutarate in fermentation liquid are taken as raw materials of AAKG, instead of crystallization products. Tn this way, repetitive operation in purifying arginine or a-ketoglutarate from fermentation broth can be avoided. Flocculation, filtration, resin adsorption, elution, concentration, crystallization, dryness and other steps shall be adopted to extraction L-arginine or ct-ketoglutarate from fermentation liquid. In the present invention, fermentation liquid is directly used to perform mixing (chelation), concentration, crystallization and preparation in certain proportion. In this way, production process of L-arginine or ct-ketoglutarate as well as preparation process of AAKG can be connected and improved, the production gap can be shortened, the production cost can be reduced and quality control level can be improved.
Compared with existing technique, the method (prepare AAKG crystal directly from fermentation liquid) in the present invention has following remarkable advantages: (1) the crystal is directly prepared from L-arginine fermentation liquid and cz-ketoglutarate fermentation liquid, AAKG production is integrated to post-extraction process of fermentation products. Therefore, the entire production flow is shortened and the manufacturing cost is reduced remarkably; (2) purification step in arginine fermentation and a-ketoglutarate preparation fermentation process are eliminated. Therefore, energy and substance consumption, waste water generation are reduced; (3) the technology possesses great flexibility.
By proper parameter adjustment, AAKG in two mixture ratios or several mixture ratios can be produced; (4) product quality can be controlled easily. Purity of AAKG can effectively guarantee by low temperature crystallization, organic solvent recrystallization technology and discoloration with activated carbon.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is an execution example; L-arginine ct-ketoglutarate HPLC ehromatograph, column Waters Atantis dC 18, mobile phase 20 mmol/L NaH2PO4 -Na2HPO4, pH 2.7, column temperature 30 °C,UY 210 mm
DESCRIPTION OF THE PREFERRED EMBODIMENTS
In the present invention, starch glucose of plant origin is used as carbon source and non-transgenic microorganism is used as fermentation strain (refer to methods in patent CN 03112896.3 and patent CN 200310106298.6) to obtain fermentation broth containing metabolic products of L-arginine or a-ketoglutarate. L-arginine -a -ketoglutarate crystal is directly prepared from the fermentation broth. The process involves fermentation liquid pretreatment, chelation, concentration, crystallization, dissolution discoloration, recrystallization, crystal dryness and other technique.
Here, technical parameters presented in the invention are described based on technique optimization, improvement of product quality, and reduction of technique cost.
Fermentation liquid pretreatment unit is to eliminate cells and large solid particles. Macrornolecular substance content in the fermentation broth can be further reduced by adding flocculant. A good flocculation effect can be obtained through CaCl2 flocculation. In scaled-up preparation process, plate-and-frame filtering, vacuum filtering or band type filtering device can be adopted. In small sample process, a centrifuge can be adopted for solid-liquid separation.
Before acidification, L-arginine and a-ketoglutarate content in two fermentation filter liquor are measured respectively. Generally, L-arginine content in fermentation broth is 4%-6% (mass and volume percent, same in following contents), a-ketoglutarate content is 3%4%. Optimization should be performed according to target products. While preparing MAAKG, molar weight of a-ketoglutarate added shall be 0.8-4.5 of L-arginine molar weight. The optimization range is within 0.95--i.05. However, molar weight of added ct-lcetoglutarate shall be 0.2-0.8 of L-arginine molar weight while preparing DAAKG. The optimization range is within 0.35-0.55.
Mixture solution of L-arginine and a-ketoglutarate is concentrated so that AAKG can reach hypersaturated state. An ideal concentration device shall be in vacuum concentration mode. Multiple-effect vacuum concentration device is more feasible for large-scale preparation process, while membrane concentration or rotary distillatory is suitable for in small-scale preparation. Take original volume of L-arginine and ct-ketoglutarate solution before mixture as the standard, concentrate the solution to 1 5%-50% of the original volume. The proper concentrated volume is 20%-25%. In this method, the larger the concentration volume, the higher crystallization recovery and lower purity; the less the concentration volume, the less crystallization recovery, the higher purity and prolonged crystallization time.
is Furthermore, chelation operation can be performed after concentration operation. However, after concentration is completed, system volume may be increased due to the addition of ct-ketoglutarate solution. This situation should be avoided.
The proper crystallization temperature is within -5 ° C 15 ° C, and the preferred temperature is within 5 ° C 10 ° C. In large-scale production, crystallizer tank is used. System cooling is performed with coolant and the cooling rate should be controlled. The preferred cooling rate is within 2 ° C 5 °C/h, the crystallization time is control within 450h, and the preferred time is 2030h.
Crystals are dissolved in 2-5 times of deionized water, the preferred volume is 3 times of water. The amount of particle activated carbon shall be adjusted properly according to crystal purity, and the preferred adding amount is 0.5%-1.5%. Proper decolorization temperature is 60 ° C -90 °C, and maintain the temperature for 30'-óomin. Filter liquor is collected after plate-frame filter. In small-scale production, AAKG filter liquor can be obtained through centrifugation or vacuum filtration.
Re-crystallization is performed in organic solvent system, and the preferred solvents are ethanol or acetone; preferred adding volume is 2 times. The re-crystallization time is 830h. After separation, crystals are obtained through filtration and washed with small amount of cold and fresh solvent for twice or three times, usually ethanol or acetone of over 50%. The wash solvent should be pre-cooled to crystallization temperature (5 ° C -10 ° C) to reduce the solubility to AAKG.
Re-crystallization can be directly operated in a water phase instead of organic solvent in. perform recrystallization. AAKG purity can also be improved, which can be determined according to quality standard of product. When recrystallization is performed in a water phase, 2 times water volume should be used to dissolve the crystal, and the crystal can be heated to accelerate dissolving rate.
Vacuum drying is generally used for crystal dryness within 60 °C 90 ° C. The preferred temperature is 70 ° C 75 °C. A pneumatic conveying dryer can be adopted in large-scale production.
The present invention content does not specify mother solution processing and solvent recovery. In implementation phase, the general or improved measure in the area can be adopted to improve the production yield and reduce waste release.
In order to elaborate on process of the present invention, specific execution cases are adopted to describe the content.
EXAMPLES
Example 1
Preparation of Mono arginine ketoglutarate MAAKG Add 25g CaC12 powder in 5L arginine fermentation liquid. Mix them sufficiently and put the solution statically for 2h. Centrifuge the solution in batch through high-capacity centrifuge (8000 r/min, 10 mm). Collect filter liquor in 4.6 L. L-arginine concentration is calculated to be 45.Og/L. The solution contains 1.1 9mol L-arginine in total. et-Ketoglutarate fermentation filtration liquid is pretreated according to similar method and the molar amount is calculated.
It is calculated that the L-arginine:ct-ketoglutarate molar ratio is equal to 1:1.
Stir the solution while slowly adding a-ketoglutarate fermentation filtration liquid into L-arginine fermentation filtration liquid so that they are mixed completely.
Adopt a rotary distillator to concentrate mixed liquor under 65 °C water bath temperature and l200mL concentrated solution is obtained. The solution volume is 26.1% of L-arginine and a-ketoglutarate fermentation filtration liquid before mixing. Leave the solution in a S °C refrigerator still for 20h, and large crystals are precipitated from the solution.
Through vacuum filtration, 272.3g (dry weight) crude product crystal is collected and the recovery ratio calculated is 71.5%. Through HPLC measurement, the crude product purity is 92.0% (without crystal water, same hereinafter), L-arginine:ct-ketoglutarate molar ratio is 1:1.11.
Take 270g crude product and dissolve in 500mL deionized water (2.5 times water volume of crude product). Active carbon powder (100 meshes) is added to 0.5% of crude product quality. Stir and decolorize the solution. Heat the solution to °C and maintain the condition for 40 mm. Perform vacuum filtration and then eliminate active carbon.
After the filter liquor is cooled to room temperature. Slowly add ethanol in 3 times volume. Leave the solution under room temperature for 50h, and then perform re-crystallization. Perform vacuum filtration and collect crystals. Wash crystals with 10-i 5mL of 85% (volume percent) ethanol for 3 times. Further dry crystals for 20 min'-30 mm. Transfer crystals to watch glass, which shall be put into vacuum drying oven under 70 °C and dried for 48 hours.
After dryness, the recrystalliscd product quality is 239.6g. Product purity is 99.2% by HPLC measurement. Where L-arginine:a-ketoglutaratc molar ratio is 1:1.06. Re-crystallised yield is 88.0%. Total yield of AAKG is 62.9%.
Example 2
Preparation of Di-arginine ketoglutaratc DAAKG Add 2SmL 1.0% chitosan hydrochloric acid (1.0%) in 5L arginine fermentation liquid. Stir and put it statically for 1.Oh. Perforrrt vacuum filtration and collect 4.2L filter liquor. It is measured that L-arginine content is 52.Og/L. It is calculated that there is totally 1.25mol L-arginine in the solution. fermentation filter liquor from a-ketoglutarate fermentation is obtained according to same method.
Take fermentation filter liquor with 91.6g a-ketoglutaratc (add filter liquor according to L-arginine: a-kctoglutaratc = 1:0.5 molar ratio). Slowly add the filter liquor into L-arginine fermentation liquid while stirring the mixture at the same time so that they can mix completely. Adopt a rotary distillatory to concentrate mixed liquor under 65 °C water bath and obtain 1680 mL concentrated solution, which is 40% volume of L-arginine and a -ketoglutarate fermentation filtration liquid before mixing. Put the mixture into 0 ° C refrigerator and leave statically for 48h. Crystals are precipitated from the solution.
Perform vacuum filtration to collect crude product crystal. The converted dry weight is 190.3g (dry weight). The recovery ratio is calculated to be 61.4%. It is measured through HPLC that the crude product purity is 88.6%, L-arginine: a-ketoglutarate mol ratio is 1.92:1.
Take 1 85g crude product and dissolve it in 370mL deionized water (2.0 times of the volume of crude product). Add active carbon powder (100 meshes) in 0.5% of crude product quality. Stir and decolorize the solution. Heat the solution to 70 C and maintain for 40 mm. Perform vacuum filtration and then eliminate active carbon to obtain 350mL filter liquor.
After the filter liquor is cooled to room temperature. Slowly add l400mL acetone (4 times filter liquor volume). Leave the solution into a 0 °C refrigerator for 8h. After crystallization, collect crystals by vacuum filtration, wash crystals with 1 0-4 SmL 0 °C acetone for 3 times, further vacuum dry crystals for 20 min-30 mm. Transfer crystals to watch glass, which shall be put into vacuum drying oven under 70 °C for 24 h to obtain DAAKG product.
Recrystal product is 165.1g. Product purity is measured to be 98.7% by HPLC, where L-arginine: ct-ketoglutarate molar ratio is 1.99:1. Re-crystal yield is 86.7%, and total yield of AAKG is 53.3%.
Example 3
AAKG preparation technology under pilot plant test scale Take S m3 L-arginine fermentation liquid containing 48g/L arginine. Add 25kg CaCl2 powder, stir the mixture so that they can dissolve completely. Put the solution statically for 2h. Adopt plate-frame filter plant (about 25.0m2 filtration area for filtration. Wash the filtration residue. Collect 4350L clarification filter liquor.
The pretreatment process for fermentation broth of ct-ketoglutarate is similar to L-arginine. The ct-ketoglutarate content in clarification filter liquor is 39.2g/L.
Taking MAAICG production as the example, add ct-ketoglutarate fennentation filtration liquid into L-arginine filtration liquid according to L-arginine: a-ketoglutarate =1:1 molar ratio. Stir the mixture evenly; the mixed fermentation liquid is 8.82 m3 in total.
Adopt double-effect vacuum concentration device to concentrate the solution to l 500L. Amount of concentrated solution is 3 4.5% of original volume of L-arginine filter liquor and ct-ketoglutarate filter liquor.
Crystallize concentrated solution mentioned above with a crystallizer tank connected with cooling water. When the filter liquor temperature is cooled to 30 C, control the cooling rate at 2 ° per hour to 5 °C. Stirring speed of crystallizer tank is l-45 r/min.. Incubate crystals for I Oh. Adopt plate-frame filtration to separate raw crystal. The raw crystal is 342.7Kg in dry weight afler conversion.
Crude product purity is 88.6% and the recovery ratio is 79.1%.
Dissolve crude product in 600L deionized water. Add 1 SOOg active carbon powder (100 meshes). Stir and heat the solution to 70 ° C, decolorize the solution for 60 mm. Eliminate active carbon with plate-frame filtration method. Fill the filter liquor into a crystallizing tank connected with cooling water and cool the filter liquor to room temperature. Add 1 800L 96% (v/v) ethanol slowly, cool the solution to 15 ° C, leave the solution still for 1 2h. Perform vacuum filtration and wash crystals with 96% (v/v) ethanol, dry crystals under 50 ° C in vacuum condition, then 222.4kg re-crystal AAKG can be obtained.
MAAKG preparation process is as described above. Total yield of the product is about 57.3% with more than 99.0% product purity. If the mother solution is recycled after treatment, the actual yield is more than 70%.
Example 4
Influence of a-ketoglutarate addition on purity and yield of crystallization product In order to study the effect of ct-ketoglutarate addition amount on purity and productivity of crystallization products, various amount of ix-ketoglutarate is added into 1 OOmL L-arginine filter liquor. The process is performed according to concentration and crystallization method in "the first implementation ease". It is measured by HPLC that purity and productivity under different batches are as follows.
Table I Influence of a-ketoglutarate addition on crystallization productivity and purity cc-ketoglutarate KG:Arg L-arginine MAAKG MAAKG (1(G) /mol:mol (Arg)/mol yield/% purity 1% /mol 0.025 0.020 0.8 55.1 92.7 0.025 0.025 1.0 71.5 92.0 0.025 0.030 1.2 67.5 91.0 0.025 0.035 1.4 60.0 89.0 0.025 0.040 1.6 57.7 87.0 The amount of a-ketoglutarate added can be adjusted within certain range.
However, compared to MAAKG, the optimal ratio is 1:1.
Example 5
Effect of crystallization temperature and cooling rate on product yield and purity Cooling rate has certain effect on crystallization yield and product purity.
According to solution system in "the fourth ease implemented" (Arg:KG = 1:1), each group is pre-eooled to 30 ° C and then adopt different cooling rate and crystallization temperature. MAAKG crystal yield and product purity is shown in
table below.
Table 2 Affect of crystallization temperature and cooling rate on productivity and purity Crystallization MAAKG MAAKG Cooling rate -__temperature yield/% purity / % °C 24 °C/h 20.7 98.8 "C Rapid cooling, 0.5 lh 22.2 97.7 "C 24 "C/h 60.6 96.4 "C Rapid cooling, 0.5 lh 67.5 95.0 "C 2-4 "C/h 71.5 92.0 "C Rapid cooling, 0.5 -lb 74.7 87.0
Example 6
HPLC measurement of AAKG Weigh 0.1 OOg MAAKG product to be measured, and dissolve in 1 OOmL distilled water as the sample to be measured. HPLC analysis conditions are: Waters Atantis dCl8 column, 2Ommol/L NaH2PO4 -Na2HPO4, pH 2.7 mobile phase. Set the column temperature as 30 C. Use a UV-detector with 21 Onm detection wavelength. The sample injection volume is lOj.tL.
Two compounds L-arginine and a-ketoglutarate are dissociated from MAAKG in water solution, and therefore two peaks are observed in HPLC chromatograph (see Figure attached). These two peaks can be obtained by using above HPLC condition with retention time of 3.35 mm and 5.79 mm respectively. Standard samples of L-arginine, ci-ketoglutarate are used to confirm that these two peaks are L-arginine and ix-ketoglutarate respectively. Sample content can be calculated according to the standard sample, and molar ratio of L-arginine, ct-ketoglutarate can be calculated at the same time.
Claims (8)
- CLAIMS: 1. A method or process for the preparation of L-arginine-ct-ketoglutarate from fermentation broth, characterized in that the required raw materials L-arginine and ct-ketoglutarate are obtained from a fermentation product, which is called fermentation broth for short, that starch glucose of plant origin is used as a carbon source and that a non-transgenic wild-type microbe is used as a fermentation strain, the preparation processes comprises: fermentation broth pretreatment, chelation, concentration, crystallization, dissolution discoloration, recrystallization and crystal drying, L-arginine fermentation broth pretreatment, elimination of cells and macromolecule impurities; wherein purified ct-ketoglutarate fermentation filter liquor is added, this process being called chelation, the mixture is evaporated and concentrated in vacuum to obtain L-argininc-a-ketoglutarate crude product with cooling and crystallization; crude products arc further treated by dissolving decolorization and organic solvent recrystallization; finally, L-arginine-ct-ketoglutarate in high purity can be obtained by drying.
- 2. The method of claim 1, wherein the process of fermentation broth pretreatment is that to flocculate, filtrate or centrifuge L-arginine fennentation liquid or ct-ketoglutarate fermentation liquid respectively to remove cells and large solid particles to obtain clarified L-arginine and a-ketoglutarate fermentation filter liquor; wherein in the flocculation operation aluminum sulfate, calcium chloride, polyacrylamide, chitosan and other flocculants or other commercial inorganic aluminium salt, molysite, calcium salt and polymeric flocculant was adopted; filtration operations including plate-and-frame filtering, vacuum filtering or band type filter devices, etc. are adopted for filtration; the process being especially suitable for large-scale preparation technology; and a centrifugation device is suitable for solid-liquid separation in small-scale preparation process.
- 3. The method of claim 1, wherein the process of chelation is that to add certain amount of a-ketoglutarate fermentation filter liquor or a-ketoglutarate solution in accordance with L-arginine content in filter liquor for chelation reaction; the molar weight of a-ketoglutarate added being 0.3-4.5 times the L-arginine molar weight in the system.
- 4. The method of claim 1, wherein the concentration process is that to concentrate chelate solution containing L-arginine and a-ketoglutarate so that AAKG can reach to hypersaturated state; the preferred concentration devices being vacuum concentration, double-effect concentration or triple-effect concentration device; the solution being concentrated to 15% 50% of original volume of L-arginine and a -ketoglutarate solution mixture.
- 5. The method of claim 1, wherein the process of crystallization is that to leave the concentrated solution under -5 15 for crystallization or use a crystallizer tank to cool solution with coolant. The crystallization process is controlled with 4'-SO hours. In the end, adopt filtration or centrifügation to collect crystals.
- 6. The method of claim 1, wherein the process of dissolving and decolorization is that to dissolve above crystals again in 2'-' 5 times of deionized water, stir the mixture so that it can be dissolved completely. Add activated carbon particle into the mixture for decolorization. The amount of activated carbon added is equivalent to 0.5%'-3.0% of AAKG crystal quality. Stir and then heat the solution to 40'-90D for 20'-60 minutes. In the end, collect AAKG filter liquor through plate-and-frame filtering.
- 7. The method of claim 1, wherein the process of recrystallization is that to slowly add hydrophilieity organic solvent of 1 -4 times of solution volume into above AAKG filter liquor. Perform recrystallization after it is incubated under room temperature or in refrigerator statically for 8 SOb. Collect crystals through filtration and wash the crystal for 2'--3 times with small amount of cold solvent.The mentioned hydrophilieity organic solvents include ethanol, methanol, acetone, isopropanol, glycerol, acetonitrile etc., where the preferred solvent is ethanol or acetone.
- 8. The method of claim 1, wherein the process of crystal drying is that to adopt vacuum drying, heated air circulation oven or pneumatic conveying, the drying temperature is between SOLI-JSOLJ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105650205A CN102020593B (en) | 2010-11-29 | 2010-11-29 | Process for preparing L-arginine-alpha-ketoglutarate (AAKG) from fermentation liquor through direct crystallization |
PCT/CN2011/000629 WO2012071766A1 (en) | 2010-11-29 | 2011-04-11 | Preparation method of l-arginine-α-ketoglutarate by direct crystallization from zymotic fluid |
Publications (3)
Publication Number | Publication Date |
---|---|
GB201111221D0 GB201111221D0 (en) | 2011-08-17 |
GB2485862A true GB2485862A (en) | 2012-05-30 |
GB2485862B GB2485862B (en) | 2013-09-04 |
Family
ID=44511925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1111221.6A Expired - Fee Related GB2485862B (en) | 2010-11-29 | 2011-04-11 | Preparation process of L-arginine-alpha-ketoglutarate by direct crystallization from fermentation broth |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2485862B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113527413B (en) * | 2021-07-29 | 2023-08-11 | 山东华辰生物化学有限公司 | Antibacterial peptide crude liquid separation and purification device and method |
CN115448885A (en) * | 2022-10-24 | 2022-12-09 | 生工生物工程(上海)股份有限公司 | Imidazole purification method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1441055A (en) * | 2003-02-25 | 2003-09-10 | 江南大学 | L-arginine producing strain and its mutation method and usage in producing L-arginine |
CN1544642A (en) * | 2003-11-13 | 2004-11-10 | 江南大学 | Method for microbial fermentation synthesis of alpha- ketoglutaric acid |
CN101591271A (en) * | 2008-05-27 | 2009-12-02 | 上海汉飞生化科技有限公司 | A kind of preparation method of crystal L-arginine alpha-ketoglutarate |
CN102020593A (en) * | 2010-11-29 | 2011-04-20 | 广东环西生物科技股份有限公司 | Process for preparing L-arginine-alpha-ketoglutarate (AAKG) from fermentation liquor through direct crystallization |
-
2011
- 2011-04-11 GB GB1111221.6A patent/GB2485862B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1441055A (en) * | 2003-02-25 | 2003-09-10 | 江南大学 | L-arginine producing strain and its mutation method and usage in producing L-arginine |
CN1544642A (en) * | 2003-11-13 | 2004-11-10 | 江南大学 | Method for microbial fermentation synthesis of alpha- ketoglutaric acid |
CN101591271A (en) * | 2008-05-27 | 2009-12-02 | 上海汉飞生化科技有限公司 | A kind of preparation method of crystal L-arginine alpha-ketoglutarate |
CN102020593A (en) * | 2010-11-29 | 2011-04-20 | 广东环西生物科技股份有限公司 | Process for preparing L-arginine-alpha-ketoglutarate (AAKG) from fermentation liquor through direct crystallization |
Also Published As
Publication number | Publication date |
---|---|
GB201111221D0 (en) | 2011-08-17 |
GB2485862B (en) | 2013-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106117072B (en) | A kind of levodopa crystalline powder and its manufacture method | |
CN102020593B (en) | Process for preparing L-arginine-alpha-ketoglutarate (AAKG) from fermentation liquor through direct crystallization | |
CN104098569A (en) | Medicinal folic acid purifying method | |
CN106117071B (en) | A kind of membrane filtration isolation and purification method of levodopa conversion fluid | |
CN111960972B (en) | Preparation process and application of taurine magnesium salt and taurine magnesium complex | |
CN113185485B (en) | Semi-synthesis method of dihydroquercetin | |
CN101125809B (en) | Solvent-free heating-free method for synthesizing potassium diformate | |
CN114287603A (en) | Method for improving color intensity of monosodium glutamate product | |
GB2485862A (en) | Preparation process of L-arginine-alpha-ketoglutarate by direct crystallisation from fermentation broth | |
CN101843587B (en) | Method for preparing ornithine aspartate powder injection for injection | |
CN111892498A (en) | Method for extracting L-malic acid | |
CN110606863B (en) | Preparation method of N-acetylneuraminic acid dihydrate | |
CN110372528B (en) | Method for purifying valine | |
CN114702487B (en) | Purification method of lysergic acid | |
CN114644580B (en) | Treatment method for producing crude L-cystine mother liquor by enzyme method | |
CN113429448B (en) | Method for extracting inosine from fermentation liquor | |
CN101817758B (en) | Preparation method of L-valine nitrate | |
CN117866803A (en) | Monosodium glutamate production method | |
RU2192470C2 (en) | Method of fusidic acid preparing | |
CN109836464B (en) | Preparation method of fructose calcium diphosphate | |
CN111116392A (en) | Lysine hydrochloride compound and pharmaceutical composition thereof | |
WO2006051940A1 (en) | L-ornithine crystal and process for producing the same | |
CN114369020A (en) | Preparation method of anhydrous calcium gluconate | |
CN110092729A (en) | A kind of method for crystallising of L lysine HCL | |
CN114349652A (en) | Preparation method of L-lysine aspartate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20190701 |